摘要
Dear editor,Renal cancer accounts for approximately 2%of all can-cer deaths worldwide,and renal cell carcinoma(RCC)is the predominant subtype[1].Radiotherapy and chemo-therapy have been found to have limited roles in the treatment of RCC.However,the treatment outcomes of metastatic RCC(mRCC)have been improved drastically since the application of molecular targeted therapeutic agents such as tyrosine kinase inhibitors(TKIs).TKIs have been gradually used for the preoperative treatment of RCC.
基金
This study was supported by the research project of Shanghai Science and Technology Commission(18ZR1423200)
the Incubating Program for Clinical Research and Innovation of Renji Hospital(PYXJS16-008)
the Shen Kang 3-year action plan program(16CR3062B)
